149 related articles for article (PubMed ID: 35999506)
1. Fentanyl activates ovarian cancer and alleviates chemotherapy-induced toxicity via opioid receptor-dependent activation of EGFR.
Xiao K; Zheng Q; Bao L
BMC Anesthesiol; 2022 Aug; 22(1):268. PubMed ID: 35999506
[TBL] [Abstract][Full Text] [Related]
2. Morphine stimulates cervical cancer cells and alleviates cytotoxicity of chemotherapeutic drugs via opioid receptor-dependent and -independent mechanisms.
Yu Z; Jin S; Tian S; Wang Z
Pharmacol Res Perspect; 2022 Oct; 10(5):e01016. PubMed ID: 36200813
[TBL] [Abstract][Full Text] [Related]
3. Analgesic effects of systemic fentanyl on cancer pain are mediated by not only central but also peripheral opioid receptors in mice.
Shinohara A; Andoh T; Saiki I; Kuraishi Y
Eur J Pharmacol; 2018 Aug; 833():275-282. PubMed ID: 29886241
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.
Yu Y; Zhang M; Zhang X; Cai Q; Hong S; Jiang W; Xu C
J Hematol Oncol; 2014 May; 7():39. PubMed ID: 24886678
[TBL] [Abstract][Full Text] [Related]
5. The pro- and anti-cancer effects of oxycodone are associated with epithelial growth factor receptor level in cancer cells.
Yu Y; Li D; Duan J; Xu H; Li L; Tan D; Yan H
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 31967294
[TBL] [Abstract][Full Text] [Related]
6. Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance.
Mori T; Kuzumaki N; Arima T; Narita M; Tateishi R; Kondo T; Hamada Y; Kuwata H; Kawata M; Yamazaki M; Sugita K; Matsuzawa A; Baba K; Yamauchi T; Higashiyama K; Nonaka M; Miyano K; Uezono Y; Narita M
Mol Pain; 2017; 13():1744806917740030. PubMed ID: 29056067
[TBL] [Abstract][Full Text] [Related]
7. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
[TBL] [Abstract][Full Text] [Related]
8. Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs.
Cao C; Lu S; Sowa A; Kivlin R; Amaral A; Chu W; Yang H; Di W; Wan Y
Cancer Lett; 2008 Aug; 266(2):249-62. PubMed ID: 18400375
[TBL] [Abstract][Full Text] [Related]
9. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer.
Zhao J; Tan W; Zhang L; Liu J; Shangguan M; Chen J; Zhao B; Peng Y; Cui M; Zhao S
Biochem Pharmacol; 2021 Aug; 190():114536. PubMed ID: 33794187
[TBL] [Abstract][Full Text] [Related]
10. Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo.
Kandala PK; Wright SE; Srivastava SK
J Pharmacol Exp Ther; 2012 Apr; 341(1):24-32. PubMed ID: 22205686
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl stimulates tumor angiogenesis via activating multiple pro-angiogenic signaling pathways.
Liu W; Chen Y; Xu W; Wang W; Tang L; Xia R; Zhu Q
Biochem Biophys Res Commun; 2020 Nov; 532(2):225-230. PubMed ID: 32861420
[TBL] [Abstract][Full Text] [Related]
12. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.
Zhang M; Cong Q; Zhang XY; Zhang MX; Lu YY; Xu CJ
J Cell Physiol; 2019 May; 234(5):6361-6370. PubMed ID: 30229902
[TBL] [Abstract][Full Text] [Related]
13. The cyclin-dependent kinase inhibitor AT7519 augments cisplatin's efficacy in ovarian cancer via multiple oncogenic signaling pathways.
Wang L; Chen Y; Li H; Xu Q; Liu R
Fundam Clin Pharmacol; 2022 Feb; 36(1):81-88. PubMed ID: 34212421
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
Ohta T; Ohmichi M; Shibuya T; Takahashi T; Tsutsumi S; Takahashi K; Kurachi H
Cancer Biol Ther; 2012 Apr; 13(6):408-16. PubMed ID: 22313686
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM.
Yang Z; Liu Y; Wei X; Zhou X; Gong C; Zhang T; Jin P; Xu S; Ma D; Gao Q
Curr Cancer Drug Targets; 2015; 15(3):215-26. PubMed ID: 25619386
[TBL] [Abstract][Full Text] [Related]
16. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
[TBL] [Abstract][Full Text] [Related]
17. Morphine Stimulates Migration and Growth and Alleviates the Effects of Chemo Drugs via AMPK-Dependent Induction of Epithelial-Mesenchymal Transition in Esophageal Carcinoma Cells.
Zhang J; Yao N; Tian S
Biol Pharm Bull; 2020; 43(5):774-781. PubMed ID: 32378556
[TBL] [Abstract][Full Text] [Related]
18. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
[TBL] [Abstract][Full Text] [Related]
19. Establishment of opioid-induced rewarding effects under oxaliplatin- and Paclitaxel-induced neuropathy in rats.
Mori T; Kanbara T; Harumiya M; Iwase Y; Masumoto A; Komiya S; Nakamura A; Shibasaki M; Kanemasa T; Sakaguchi G; Suzuki T
J Pharmacol Sci; 2014; 126(1):47-55. PubMed ID: 25141998
[TBL] [Abstract][Full Text] [Related]
20. Relative contributions of peripheral versus supraspinal or spinal opioid receptors to the antinociception of systemic opioids.
Khalefa BI; Shaqura M; Al-Khrasani M; Fürst S; Mousa SA; Schäfer M
Eur J Pain; 2012 May; 16(5):690-705. PubMed ID: 22337491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
